Clinical Trial Update: Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and mode of action of a long-acting activated recombinant human factor VII in patients with haemophilia A or B; trial status com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• NovoSeven (recombinant activated factor VII) (recombinant activated factor VII)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A | Phase 1 | Status: COMPLETED